Current approaches and future role of high content imaging in safety sciences and drug discovery

Erwin Van Vliet, Mardas Daneshian, Mario Beilmann, Anthony Davies, Eugenio Fava, Roland Fleck, Yvon Julé, Manfred Kansy, Stefan Kustermann, Peter Macko, William R. Mundy, Adrian Roth, Imran Shah, Marianne Uteng, Bob Van De Water, Thomas Hartung, Marcel Leist

Research output: Contribution to journalArticle

Abstract

High content imaging combines automated microscopy with image analysis approaches to simultaneously quantify multiple phenotypic and/or functional parameters in biological systems. The technology has become an important tool in the fields of safety sciences and drug discovery, because it can be used for mode-of-action identification, determination of hazard potency and the discovery of toxicity targets and biomarkers. In contrast to conventional biochemical endpoints, high content imaging provides insight into the spatial distribution and dynamics of responses in biological systems. This allows the identification of signaling pathways underlying cell defense, adaptation, toxicity and death. Therefore, high content imaging is considered a promising technology to address the challenges for the Toxicity testing in the 21st century approach. Currently, high content imaging technologies are frequently applied in academia for mechanistic toxicity studies and in pharmaceutical industry for the ranking and selection of lead drug compounds or to identify/confirm mechanisms underlying effects observed in vivo. A recent workshop gathered scientists working on high content imaging in academia, pharmaceutical industry and regulatory bodies with the objective to compile the state- of-the-art of the technology in the different institutions. Together they defined technical and methodological gaps, proposed quality control measures and performance standards, highlighted cell sources and new readouts and discussed future requirements for regulatory implementation. This review summarizes the discussion, proposed solutions and recommendations of the specialists contributing to the workshop.

Original languageEnglish (US)
Pages (from-to)479-493
Number of pages15
JournalArchivos de Medicina Veterinaria
Volume46
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Drug Discovery
image analysis
Technology
Safety
drugs
Drug Industry
toxicity testing
Education
Quality Control
toxicity
Microscopy
Biomarkers
endpoints
quality control
control methods
microscopy
mechanism of action
biomarkers
spatial distribution
Pharmaceutical Preparations

Keywords

  • Drug development
  • High content imaging
  • Mechanistic safety screening
  • Toxicity pathways
  • Toxicology

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Van Vliet, E., Daneshian, M., Beilmann, M., Davies, A., Fava, E., Fleck, R., ... Leist, M. (2014). Current approaches and future role of high content imaging in safety sciences and drug discovery. Archivos de Medicina Veterinaria, 46(4), 479-493. https://doi.org/10.14573/altex.1405271

Current approaches and future role of high content imaging in safety sciences and drug discovery. / Van Vliet, Erwin; Daneshian, Mardas; Beilmann, Mario; Davies, Anthony; Fava, Eugenio; Fleck, Roland; Julé, Yvon; Kansy, Manfred; Kustermann, Stefan; Macko, Peter; Mundy, William R.; Roth, Adrian; Shah, Imran; Uteng, Marianne; Van De Water, Bob; Hartung, Thomas; Leist, Marcel.

In: Archivos de Medicina Veterinaria, Vol. 46, No. 4, 2014, p. 479-493.

Research output: Contribution to journalArticle

Van Vliet, E, Daneshian, M, Beilmann, M, Davies, A, Fava, E, Fleck, R, Julé, Y, Kansy, M, Kustermann, S, Macko, P, Mundy, WR, Roth, A, Shah, I, Uteng, M, Van De Water, B, Hartung, T & Leist, M 2014, 'Current approaches and future role of high content imaging in safety sciences and drug discovery', Archivos de Medicina Veterinaria, vol. 46, no. 4, pp. 479-493. https://doi.org/10.14573/altex.1405271
Van Vliet, Erwin ; Daneshian, Mardas ; Beilmann, Mario ; Davies, Anthony ; Fava, Eugenio ; Fleck, Roland ; Julé, Yvon ; Kansy, Manfred ; Kustermann, Stefan ; Macko, Peter ; Mundy, William R. ; Roth, Adrian ; Shah, Imran ; Uteng, Marianne ; Van De Water, Bob ; Hartung, Thomas ; Leist, Marcel. / Current approaches and future role of high content imaging in safety sciences and drug discovery. In: Archivos de Medicina Veterinaria. 2014 ; Vol. 46, No. 4. pp. 479-493.
@article{fae10e34c23549db968b6330e526783b,
title = "Current approaches and future role of high content imaging in safety sciences and drug discovery",
abstract = "High content imaging combines automated microscopy with image analysis approaches to simultaneously quantify multiple phenotypic and/or functional parameters in biological systems. The technology has become an important tool in the fields of safety sciences and drug discovery, because it can be used for mode-of-action identification, determination of hazard potency and the discovery of toxicity targets and biomarkers. In contrast to conventional biochemical endpoints, high content imaging provides insight into the spatial distribution and dynamics of responses in biological systems. This allows the identification of signaling pathways underlying cell defense, adaptation, toxicity and death. Therefore, high content imaging is considered a promising technology to address the challenges for the Toxicity testing in the 21st century approach. Currently, high content imaging technologies are frequently applied in academia for mechanistic toxicity studies and in pharmaceutical industry for the ranking and selection of lead drug compounds or to identify/confirm mechanisms underlying effects observed in vivo. A recent workshop gathered scientists working on high content imaging in academia, pharmaceutical industry and regulatory bodies with the objective to compile the state- of-the-art of the technology in the different institutions. Together they defined technical and methodological gaps, proposed quality control measures and performance standards, highlighted cell sources and new readouts and discussed future requirements for regulatory implementation. This review summarizes the discussion, proposed solutions and recommendations of the specialists contributing to the workshop.",
keywords = "Drug development, High content imaging, Mechanistic safety screening, Toxicity pathways, Toxicology",
author = "{Van Vliet}, Erwin and Mardas Daneshian and Mario Beilmann and Anthony Davies and Eugenio Fava and Roland Fleck and Yvon Jul{\'e} and Manfred Kansy and Stefan Kustermann and Peter Macko and Mundy, {William R.} and Adrian Roth and Imran Shah and Marianne Uteng and {Van De Water}, Bob and Thomas Hartung and Marcel Leist",
year = "2014",
doi = "10.14573/altex.1405271",
language = "English (US)",
volume = "46",
pages = "479--493",
journal = "Austral journal of veterinary sciences",
issn = "0719-8000",
publisher = "Universidad Austral de Chile",
number = "4",

}

TY - JOUR

T1 - Current approaches and future role of high content imaging in safety sciences and drug discovery

AU - Van Vliet, Erwin

AU - Daneshian, Mardas

AU - Beilmann, Mario

AU - Davies, Anthony

AU - Fava, Eugenio

AU - Fleck, Roland

AU - Julé, Yvon

AU - Kansy, Manfred

AU - Kustermann, Stefan

AU - Macko, Peter

AU - Mundy, William R.

AU - Roth, Adrian

AU - Shah, Imran

AU - Uteng, Marianne

AU - Van De Water, Bob

AU - Hartung, Thomas

AU - Leist, Marcel

PY - 2014

Y1 - 2014

N2 - High content imaging combines automated microscopy with image analysis approaches to simultaneously quantify multiple phenotypic and/or functional parameters in biological systems. The technology has become an important tool in the fields of safety sciences and drug discovery, because it can be used for mode-of-action identification, determination of hazard potency and the discovery of toxicity targets and biomarkers. In contrast to conventional biochemical endpoints, high content imaging provides insight into the spatial distribution and dynamics of responses in biological systems. This allows the identification of signaling pathways underlying cell defense, adaptation, toxicity and death. Therefore, high content imaging is considered a promising technology to address the challenges for the Toxicity testing in the 21st century approach. Currently, high content imaging technologies are frequently applied in academia for mechanistic toxicity studies and in pharmaceutical industry for the ranking and selection of lead drug compounds or to identify/confirm mechanisms underlying effects observed in vivo. A recent workshop gathered scientists working on high content imaging in academia, pharmaceutical industry and regulatory bodies with the objective to compile the state- of-the-art of the technology in the different institutions. Together they defined technical and methodological gaps, proposed quality control measures and performance standards, highlighted cell sources and new readouts and discussed future requirements for regulatory implementation. This review summarizes the discussion, proposed solutions and recommendations of the specialists contributing to the workshop.

AB - High content imaging combines automated microscopy with image analysis approaches to simultaneously quantify multiple phenotypic and/or functional parameters in biological systems. The technology has become an important tool in the fields of safety sciences and drug discovery, because it can be used for mode-of-action identification, determination of hazard potency and the discovery of toxicity targets and biomarkers. In contrast to conventional biochemical endpoints, high content imaging provides insight into the spatial distribution and dynamics of responses in biological systems. This allows the identification of signaling pathways underlying cell defense, adaptation, toxicity and death. Therefore, high content imaging is considered a promising technology to address the challenges for the Toxicity testing in the 21st century approach. Currently, high content imaging technologies are frequently applied in academia for mechanistic toxicity studies and in pharmaceutical industry for the ranking and selection of lead drug compounds or to identify/confirm mechanisms underlying effects observed in vivo. A recent workshop gathered scientists working on high content imaging in academia, pharmaceutical industry and regulatory bodies with the objective to compile the state- of-the-art of the technology in the different institutions. Together they defined technical and methodological gaps, proposed quality control measures and performance standards, highlighted cell sources and new readouts and discussed future requirements for regulatory implementation. This review summarizes the discussion, proposed solutions and recommendations of the specialists contributing to the workshop.

KW - Drug development

KW - High content imaging

KW - Mechanistic safety screening

KW - Toxicity pathways

KW - Toxicology

UR - http://www.scopus.com/inward/record.url?scp=84926335357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926335357&partnerID=8YFLogxK

U2 - 10.14573/altex.1405271

DO - 10.14573/altex.1405271

M3 - Article

C2 - 25027442

AN - SCOPUS:84910608382

VL - 46

SP - 479

EP - 493

JO - Austral journal of veterinary sciences

JF - Austral journal of veterinary sciences

SN - 0719-8000

IS - 4

ER -